The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Growth In Market Value Is Anticipated For The Next Generation Complement Therapeutics Market Between 2026 And 2030?
The next generation complement therapeutics market size has experienced rapid growth in recent years. It is projected to expand from $7.38 billion in 2025 to $8.56 billion in 2026, at a compound annual growth rate (CAGR) of 16.0%. The historical growth of this market can be attributed to several factors, including the limited availability of complement-targeting therapeutics, a reliance on conventional immunosuppressive therapies, the increasing prevalence of rare hematologic and autoimmune disorders, regulatory approvals for first-generation complement inhibitors, and a rise in clinical trials in hematology and ophthalmology.
The next generation complement therapeutics market size is anticipated to experience rapid growth in the upcoming years. It is projected to expand to $15.29 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 15.6%. The expansion during this forecast period can be attributed to the development of novel c3, c5, factor b, and factor d inhibitors, the broadening of combination therapy approaches, the increasing adoption of gene and RNA-based medicines, rising investment in rare disease research, and growing healthcare expenditure on advanced immune therapies. Significant trends for the forecast period include the increasing uptake of targeted complement therapies for rare diseases, the development of monotherapy and adjunctive therapy strategies, a rise in the use of biologics and small molecule complement inhibitors, the expansion of applications within ophthalmology, hematology, and immunology, and the integration of personalized medicine with gene-based therapeutics.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27360&type=smp
Which Growth Drivers Are Expected To Support The Next Generation Complement Therapeutics Market Forward?
The expansion of the next-generation complement therapeutics market is anticipated, propelled by the increasing occurrence of chronic diseases. These persistent health conditions necessitate continuous management to alleviate symptoms and enhance patients’ quality of life. The uptick in chronic diseases stems from inactive lifestyles, which restrict physical movement, disturb metabolic processes, and heighten enduring health hazards. Next-generation complement therapeutics address chronic illnesses through precise targeting and regulation of the hyperactive complement system, thereby decreasing inflammation and guarding against tissue harm. For example, data from June 2024, released by the UK-based National Health Service, indicated that 3,615,330 individuals registered with a general practitioner (GP) had a diagnosis of non-diabetic hyperglycemia or pre-diabetes (a state characterized by elevated blood sugar not yet meeting diabetes criteria) in 2023. This represented an 18% surge from 3,065,825 instances recorded in 2022. Consequently, the growing incidence of chronic diseases is fueling the expansion of the next-generation complement therapeutics market.
Which Segment Divisions Form The Structure Of The Next Generation Complement Therapeutics Market?
The next generation complement therapeutics market covered in this report is segmented –
1) By Type Of Therapy: Monotherapy, Adjunctive Therapy
2) By Molecule Type: Biologic, Small Molecule
3) By Route Of Administration: Intravenous, Oral, Intravitreal, Subcutaneous
4) By Indication: Paroxysmal Nocturnal Hemoglobinuria, Geographic Atrophy (GA) Secondary To Age-Related Macular Degeneration, Generalized Myasthenia Gravis, Atypical Hemolytic Uremic Syndrome, Other Indications
5) By Therapeutic Area: Hematology, Ophthalmology, Neurology, Immunology Or Rheumatology, Other Therapeutic Areas
Subsegments:
1) By Monotherapy: C3 Inhibitors, C5 Inhibitors, Factor D Inhibitors, Factor B Inhibitors, C1 Inhibitors, MASP-2 Inhibitors
2) By Adjunctive Therapy: Combination With Immunosuppressants, Combination With Steroids, Combination With Plasma Exchange, Combination With Biologics, Combination With Chemotherapeutics, Combination With Anticoagulants
What Trends Are Influencing The Future Of The Next Generation Complement Therapeutics Market?
Companies operating in the Next Generation Complement Therapeutics market are primarily focused on developing innovative solutions, such as targeted C5 complement inhibitors, to cater to the growing demand for effective treatments for rare and severe complement-mediated diseases. Targeted C5 complement inhibitors are designed to specifically block the C5 protein in the complement cascade, thereby preventing the formation of the membrane attack complex, which is a vital step in immune-mediated tissue damage. For instance, in February 2024, Chugai Pharmaceutical Co., Ltd., a Japan-based biopharmaceutical company, introduced PEGPH20 (Pegcetacoplan), an innovative C5-targeted complement inhibitor. PEGPH20 is a synthetic peptide conjugate engineered to selectively inhibit complement C5 activation, consequently preventing hemolysis and inflammation linked to conditions like paroxysmal nocturnal hemoglobinuria (PNH) and other complement-driven disorders. This therapy offers benefits such as subcutaneous administration, improved patient compliance, and a favorable safety profile compared to traditional systemic complement inhibitors.
Which Organizations Are Involved In The Next Generation Complement Therapeutics Market?
Major companies operating in the next generation complement therapeutics market are AstraZeneca PLC, Novartis AG, Amgen Inc., Regeneron Pharmaceuticals Inc., Genentech Inc., Genmab A/S, Mallinckrodt Pharmaceuticals Ltd., Alnylam Pharmaceuticals Inc., Apellis Pharmaceuticals Inc., Omeros Corporation, CANbridge Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., Molecular Partners AG, NovelMed Therapeutics Inc., InflaRx GmbH, Amyndas Pharmaceuticals S.A., Kira Pharmaceuticals Inc., ReAlta Life Sciences Inc.
Access The Complete Next Generation Complement Therapeutics Market Report:
Which Region Accounts For The Highest Share Of The Next Generation Complement Therapeutics Market?
North America was the largest region in the next generation complement therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next generation complement therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Next Generation Complement Therapeutics Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=27360&type=smp
Browse Through More Reports Similar to the Global Next Generation Complement Therapeutics Market 2026, By The Business Research Company
Payment Gateway Market Report 2026
https://www.thebusinessresearchcompany.com/report/payment-gateway-global-market-report
Payment Processor Market Report 2026
https://www.thebusinessresearchcompany.com/report/payment-processor-global-market-report
Quantum Technology Market Report 2026
https://www.thebusinessresearchcompany.com/report/quantum-technology-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model